GSK agrees to publish clinical trial data

Glaxosmithkline has agreed to publish vastly more of its clinical trial data, in a move long championed by transparency advocates.

The company said Tuesday it would release clinical study reports (CSRs) for all newly approved drugs in future, as well as for those already approved, dating back to the formation of GSK.

CSRs are the full-length trial reports held by companies, parts of which are submitted to regulators. They contain huge amounts of detail on design, methods and results but are rarely made available in their entirety.